Skip to Content

M R7 (Rabeprazole Sodium Delayed-Release 20 mg)

Pill with imprint M R7 is Beige, Round and has been identified as Rabeprazole Sodium Delayed-Release 20 mg. It is supplied by Mylan Pharmaceuticals Inc..

Rabeprazole is used in the treatment of barrett's esophagus; gerd; erosive esophagitis; duodenal ulcer; duodenal ulcer prophylaxis (and more), and belongs to the drug class proton pump inhibitors. There is no proven risk in humans during pregnancy. Rabeprazole 20 mg is not a controlled substance under the Controlled Substances Act (CSA).

Images for M R7

Rabeprazole sodium delayed-release 20 mg M R7
Rabeprazole sodium delayed-release 20 mg M R7  Front
Rabeprazole sodium delayed-release 20 mg M R7  Back
Rabeprazole sodium delayed-release 20 mg M R7

Rabeprazole Sodium Delayed-Release

Imprint:
M R7
Strength:
20 mg
Color:
Beige
Shape:
Round
Availability:
Prescription only
Drug Class:
Proton pump inhibitors
Pregnancy Category:
B - No proven risk in humans
CSA Schedule:
Not a controlled drug
Labeler / Supplier:
Mylan Pharmaceuticals Inc.
National Drug Code (NDC):
00378-6709

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide